Statement Of Cash Flows [Abstract]

Xbrane Biopharma - Filing #702449

Concept	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2020-01-01 to 2020-12-31	As at 2020-12-31	2020-01-01 to 2020-12-31	As at 2019-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)	—	188 376 SEK	188 376 SEK	226 026 SEK	—	226 026 SEK	—
Adjustments to reconcile profit (loss) [abstract]
Adjustments for decrease (increase) in inventories	—	61 086 SEK	—	—	—	51 325 SEK	—
Other adjustments for non-cash items	—	7 180 SEK	—	—	—	6 247 SEK	—
Cash flows from (used in) operations	—	181 195 SEK	—	—	—	219 779 SEK	—
Cash flows from (used in) operating activities	—	219 610 SEK	—	—	—	238 407 SEK	—
Cash flows from (used in) investing activities [abstract]
Purchase of property, plant and equipment, classified as investing activities	—	27 678 SEK	—	—	—	3 855 SEK	—
Purchase of intangible assets, classified as investing activities	—	49 672 SEK	—	—	—	—	—
Cash flows from (used in) investing activities	—	77 350 SEK	—	—	—	3 855 SEK	—
Cash flows from (used in) financing activities [abstract]
Proceeds from changes in ownership interests in subsidiaries that do not result in loss of control	—	—	—	—	—	3,000 SEK	—
Proceeds from issuing shares	—	380 870 SEK	—	—	—	346 444 SEK	—
Repayments of borrowings, classified as financing activities	—	—	—	—	—	12,000 SEK	—
Payments of lease liabilities, classified as financing activities	—	7 273 SEK	—	—	—	3 127 SEK	—
Cash flows from (used in) financing activities	—	349 365 SEK	—	—	—	322 724 SEK	—
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes	—	52 406 SEK	—	—	—	80 461 SEK	—
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents	—	1 393 SEK	—	—	—	1 520 SEK	—
Cash and cash equivalents	295 180 SEK	—	—	—	243 139 SEK	—	164 197 SEK